Seer, Inc. — fact timeline

Seer, Inc. reported the quarter ended March 31, 2026 results: revenue $2.8 million, net income $16.8 million. Guidance reaffirmed.

“and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended March 31, 2026. Recent Highlights • Achieved revenue of $2.8 million in the first quarter of 2026 • Achieved a doubling of independent publications year-over-year to 84 total, accelerating third-party validation of Seer’s platform • Secured a”

Seer, Inc.: Adoption of Certificate of Designation for Series A Participating Preferred Stock (effective 2026-02-26).

“the Board approved a Certificate of Designation of Rights, Powers and Preferences of Series A Participating Preferred Stock (the “Certificate of Designation”) setting forth the rights, powers and preferences of the Preferred Stock. The Certificate of Designation will be filed with the Secretary of State of the State of Delaware to be effective on February 26, 2026.”

Seer, Inc. issued common stock.

“At the close of business on December 9, 2025, each outstanding share of Class B Common Stock, par value $0.00001 per share (the “Class B Common Stock”), of Seer, Inc. (the “Company”), automatically converted (the “Conversion”) into one share of the Company’s Class A Common Stock”

Seer, Inc.: Filed Certificate of Retirement to reduce authorized shares of capital stock and Class B Common Stock following automatic conversion of Class B to Class A shares (effective 2025-12-12).

“on December 12, 2025, the Company filed the Certificate of Retirement with the Secretary of State of the State of Delaware in connection with the retirement of the shares of Class B Common Stock that were issued but not outstanding following the Conversion and to accordingly reduce the Company's total number of authorized shares of capital stock and the Company's total number of authorized shares of Class B Common Stock by an amount equal to the number of retired shares of Class B Common Stock.”

Seer, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)(B)).

“July 7, 2025, Seer, Inc. (the "Company") notified The Nasdaq Stock Market LLC (“Nasdaq”) that following the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting"), the Company will no longer be in compliance with the Nasdaq Listing Rule 5605(c)(2)(A), which requires that (i) the Audit Committee of the Company's Board of Directors (the “Audit Committee”) be composed of at least three members, and (ii) that one member of the Audit Committee has past employment experience in finance or accounting, requisite professional certification in accounting, or any other comparable experience”

David Hallal changed role as Lead Independent Director at Seer, Inc..

“The Company also announced that Dr. Roelofs would replace David Hallal as the Company’s Lead Independent Director and would serve on the Company’s Corporate Governance and Nominating Committee and Science and Technology Committee.”

Nicolas Henry Roelofs was appointed as Lead Independent Director at Seer, Inc..

“On August 13, 2024, the board of directors (the “Board”) of Seer, Inc. (the “Company”) appointed Nicolas Henry Roelofs, Ph.D. to the Board with a term expiring at the Company’s 2025 annual meeting of the stockholders.”

Elona Kogan resigned as Chief Legal Officer and Corporate Secretary at Seer, Inc..

“On July 16, 2024, Elona Kogan resigned as the Chief Legal Officer and Corporate Secretary of Seer, Inc. (the “Company”), to pursue other career opportunities.”

Rachel Haurwitz resigned as Member of the Board of Directors at Seer, Inc..

“On July 8, 2024, Rachel Haurwitz, Ph.D. informed Seer, Inc. (the “Company”) of her resignation as a member of the Company’s Board of Directors (the “Board”) and all committees thereof, effective immediately”

Seer, Inc. reported the first quarter ended March 31, 2024 results: revenue $3.1 million. Guidance reaffirmed.

“commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights • Achieved revenue of $3.1 million for the first quarter of 2024 • Announced the expansion of the Seer Technology Access Center (STAC) program to Europe, providing researchers with end-to-end services from sample”

Seer, Inc. reported the year ended December 31, 2023 results: revenue $16.7 million, net income $86.3 million. Guidance initiated.

“and full year ended December 31, 2023. Recent Highlights • Achieved revenue of $4.4 million for the fourth quarter of 2023, a decrease of 4% over the fourth quarter of 2022, and $16.7 million for the full year 2023, an increase of 8% over the full year 2022 • Shipped 23 instruments during 2023, bringing cumulative instruments shipped to 62 as of December 31, 2023 •”

Seer, Inc. reported the quarter ended December 31, 2023 results: revenue $4.4 million, net income $17.8 million. Guidance initiated.

“a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2023. Recent Highlights • Achieved revenue of $4.4 million for the fourth quarter of 2023, a decrease of 4% over the fourth quarter of 2022, and $16.7 million for the full year 2023, an increase of 8% over the full year 2022 • Shipped 23”

Catherine Friedman resigned as Director at Seer, Inc..

“On December 21, 2023, Catherine Friedman informed Seer, Inc. (the “Company”) of her resignation as a member of the Company’s Board of Directors (the “Board”) and all committees thereof, effective immediately.”

Elona Kogan was appointed as Chief Legal Officer at Seer, Inc..

“Also on November 17, 2023, the Board appointed Elona Kogan to the office of Chief Legal Officer of the Company.”

David Horn changed role as President at Seer, Inc..

“On November 17, 2023, in connection with the promotion of David Horn to the office of President of Seer, Inc. (the “Company”), in addition to his current position as Chief Financial Officer”

Omid Farokhzad resigned as President at Seer, Inc..

“Omid Farokhzad, M.D. resigned from the position of President of the Company; he will retain his positions as Chief Executive Officer and Chair of the Board of Directors”

Seer, Inc. reported third quarter ended September 30, 2023 results: revenue $4.2 million, net income $21.1 million. Guidance lowered.

“a disruptive new platform for proteomics, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights • Achieved revenue of $4.2 million for the third quarter of 2023, an increase of 5% over the prior year period • Expanded geographically with two new partners - Danyel Biotech in Israel and GeneTiCA in Eastern”

Seer, Inc. reported the second quarter ended June 30, 2023 results: revenue $4.0 million. Guidance lowered.

“commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights • Achieved revenue of $4.0 million for the second quarter of 2023, an increase of 11% over the prior year period • Launched the Proteograph XT Assay Kit, enabling rapid proteomics across a range of sample types”

Mostafa Ronaghi, Ph.D. resigned as Director at Seer, Inc..

“On July 18, 2023, Mostafa Ronaghi, Ph.D. informed Seer, Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and all committees thereof, effective immediately.”

Seer, Inc.: Board approved an amendment and restatement of the bylaws to align with the charter amendment and include other changes (effective 2023-06-15).

“On June 15, 2023, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws (the “A&R Bylaws”) to align the Company’s bylaws with the Amendment, among other changes.”

Seer, Inc.: Filed amendment to the certificate of incorporation to phase out the classified board structure (effective 2023-06-14).

“On June 14, 2023, following the approval of the stockholders of Seer, Inc. (the “Company”) of Proposal One at the 2023 Annual Meeting of Stockholders (the “Annual Meeting”, as discussed below), the Company filed an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Amendment”) to phase out the classified structure of the Company’s Board of Directors (the “Board”).”

Seer, Inc. shareholders approved Election of Omid Farokhzad, M.D., Meeta Gulyani, David Hallal and Terrance McGuire as directors at the 2023-06-14 meeting.

“Proposal Four – Election of Directors The table below presents the voting results of the election of the four directors to the Company’s Board of Directors to serve until the 2024 annual meeting of stockholders by the Company’s stockholders: Nominee Votes For Votes Withheld Percent of Voted Broker Non-Votes Omid Farokhzad, M.D. 70,123,224 7,384,749 90.5 % 4,004,328 Meeta Gulyani 70,122,337 7,385,636 90.5 % 4,004,328 David Hallal 54,309,805 23,198,168 70.1 % 4,004,328 Terrance McGuire 56,342,550 21,165,423 72.7 % 4,004,328”

Seer, Inc. shareholders approved Non-binding advisory vote to approve named executive officer compensation at the 2023-06-14 meeting.

“Proposal Three – Non-binding Advisory Vote to Approve Named Executive Officer Compensation The Company’s stockholders elected to approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 60,841,553 12,258,019 4,408,401 4,004,328”

Seer, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-14 meeting.

“Proposal Two – Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 81,500,742 6,152 5,407 —”

Seer, Inc. shareholders approved Amendment to Certificate of Incorporation to phase out the classified structure of the Board of Directors at the 2023-06-14 meeting.

“Proposal One – Amendment to Certificate of Incorporation The table below presents the voting results of the Declassification Proposal by the Company’s stockholders: Votes For Votes Against Abstentions Broker Non-Votes 77,497,967 5,866 4,140 4,004,328”

Seer, Inc. reported the first quarter ended March 31, 2023 results: revenue $4.1 million. Guidance reaffirmed.

“We expect this momentum to continue throughout the year as more customers adopt the technology and scale their use of the platform.” Recent Highlights • Achieved revenue of $4.1 million for the first quarter of 2023, an increase of 22% over the prior year period • Announced the first protein quantitative trait loci, or pQTL, customer manuscript, demonstrating”

Seer, Inc. reported the full year ended December 31, 2022 results: revenue $15.5 million, net income $93.0 million. Guidance raised.

“new applications and markets, and continuing to build an industry-leading team. ” Recent Highlights • Achieved revenue of $4.6 million for the fourth quarter of 2022 and $15.5 million for the full year 2022, an increase of 50% and 134% over the corresponding periods of 2021 • Shipped 22 instruments during 2022, bringing cumulative instruments shipped to 39 as”

Seer, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $4.6 million, net income $22.5 million. Guidance raised.

“through presentations and publications, catalyzing new applications and markets, and continuing to build an industry-leading team. ” Recent Highlights • Achieved revenue of $4.6 million for the fourth quarter of 2022 and $15.5 million for the full year 2022, an increase of 50% and 134% over the corresponding periods of 2021 • Shipped 22 instruments during 2022,”

Seer, Inc. updated its full year 2022 guidance (reaffirmed).

“Seer continues to expect full year 2022 revenue to be in the range of $14.0 million to $16.0 million.”

Seer, Inc. reported the third quarter ended September 30, 2022 results: revenue $4.0 million, net income $24.0 million.

“Revenue was $4.0 million for the three months ended September 30, 2022, as compared to $2.2 million for the three months ended September 30, 2021. The increase was primarily due to increased sales of the Proteograph Product Suite and its related products. Product-related revenue for the third quarter of 2022 was $3.9 million, including $1.3 million of related party revenue, and consisted of sales of SP100 instruments, consumable kits and platform evaluations. Gross profit was $1.9 million and gross margin was 49% for the third quarter of 2022. Operating expenses were $27.0 million for the third quarter of 2022, including $9.1 million of stock-based compensation, as compared to $19.6 million, including $6.8 million of stock-based compensation, for the corresponding prior year period. The increase in expenses was driven by increased employee compensation and other related expenses, including stock-based compensation, and increased expenses related to the expansion of the company’s facili”

Omid Farokhzad was appointed as President at Seer, Inc..

“In addition, on August 26, 2022, the Board appointed Omid Farokhzad, M.D. to the office of President of the Company, in addition to his current positions as Chief Executive Officer and Chair of the Board, effective as of Mr. Ostadan’s resignation.”

Omead Ostadan resigned as Director at Seer, Inc..

“On August 25, 2022, Omead Ostadan resigned from his position as President of Seer, Inc. (the “Company”) and from its Board of Directors (the “Board”) for personal reasons, each effective as of September 30, 2022.”

Omead Ostadan resigned as President at Seer, Inc..

“On August 25, 2022, Omead Ostadan resigned from his position as President of Seer, Inc. (the “Company”) and from its Board of Directors (the “Board”) for personal reasons, each effective as of September 30, 2022.”

Scott Thomas was appointed as Chief Commercial Officer at Seer, Inc..

“On March 16, 2022, Seer, Inc., (the “Company”) announced that Scott Thomas has been appointed to the role of Chief Commercial Officer , effective upon commencement of his employment with the Company on March 21, 2022 (the “Effective Date”).”

Omead Ostadan changed role as President at Seer, Inc..

“Mr. Ostadan will initially return on a part-time basis as the Company’s President beginning on February 28, 2022”

Meeta Gulyani was appointed as Director at Seer, Inc..

“Contemporaneously, Meeta Gulyani was appointed to the Board.”

David Singer resigned as Director at Seer, Inc..

“On November 4, 2021, David Singer notified the Board of his intent to resign as a director, effective as of November 8, 2021.”

Rachel Haurwitz was appointed as Director at Seer, Inc..

“On November 7, 2021, Rachel Haurwitz, Ph.D. was appointed to the board of directors (the “Board”) of Seer, Inc. (the “Company”), effective as of November 8, 2021.”